Venus Concept Inc. (VERO)
Market Cap | 24.67M |
Revenue (ttm) | 107.85M |
Net Income (ttm) | -38.12M |
Shares Out | 69.33M |
EPS (ttm) | -0.58 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 250,104 |
Open | 0.360 |
Previous Close | 0.351 |
Day's Range | 0.350 - 0.374 |
52-Week Range | 0.150 - 1.690 |
Beta | 0.90 |
Analysts | Buy |
Price Target | 2.21 (+520.96%) |
Earnings Date | Mar 27, 2023 |
About VERO
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional ... [Read more]
Financial Performance
In 2021, Venus Concept's revenue was $105.62 million, an increase of 35.39% compared to the previous year's $78.01 million. Losses were -$23.01 million, -74.09% less than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for VERO stock is "Buy." The 12-month stock price forecast is $2.21, which is an increase of 520.96% from the latest price.
News

Why Is Venus Concept (VERO) Stock Up 81% Today?
Venus Concept (NASDAQ: VERO) stock is rocketing higher on Wednesday following approval for its fractional skin resurfacing technology. The U.S. Food and Drug Administration (FDA) has signed off on th...

Why Venus Concept (VERO) Shares Are Trading Higher Premarket Today?
Venus Concept Inc has received an FDA 510(k) clearance to market its AI.ME next-generation robotic technology for fractional skin resurfacing.

Venus Concept Receives 510(k) Clearance for Use of its AI.ME™ Next Generation Robotic Technology for Fractional Skin Resurfacing
Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug ...

Venus Concept Announces Completion of $6.72 Million Private Placement Financing
TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has completed a n...

Venus Concept Announces Third Quarter of Fiscal Year 2022 Financial Results
TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three...

Venus Concept Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TORONTO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has issued a stoc...

Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer
TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. He...

Venus Concept Announces Updated Release Date of November 10, 2022 for Third Quarter of Fiscal Year 2022 Financial Results
TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it is updating the r...

Venus Concept Announces Appointment of Rajiv De Silva as Chief Executive Officer and Director; Updates Fiscal Year 2022 Revenue Guidance
TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that Rajiv De Silva has b...

Venus Concept (VERO) Reports Q2 Loss, Misses Revenue Estimates
Venus Concept (VERO) delivered earnings and revenue surprises of -100% and 9.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept Announces Second Quarter of Fiscal Year 2022 Financial Results; Updates Fiscal Year 2022 Revenue Guidance
TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three...

Venus Concept to Release Second Quarter of Fiscal Year 2022 Financial Results on August 12, 2022
TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fi...

Venus Concept (VERO) Reports Q1 Loss, Misses Revenue Estimates
Venus Concept (VERO) delivered earnings and revenue surprises of -30% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept Announces First Quarter of Fiscal Year 2022 Financial Results; Reaffirms Fiscal Year 2022 Revenue Guidance
TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three ...

Venus Concept Receives New FDA 510(k) Clearance for Venus BlissMAX
Clearance Expands Indications for Use to Include Non-Invasive Lipolysis of the Back and Thighs and Increases Maximum Energy Output to 150 Watts Clearance Expands Indications for Use to Include Non-Inv...

Venus Concept Announces First Patient Treatment in Study Evaluating the Safety and Efficacy of Aime™ Next Generation Robotic Technology for the Treatment of Moderate to Severe Facial Wrinkles
TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that the first patient h...

Venus Concept to Release First Quarter of Fiscal Year 2022 Financial Results on May 12, 2022
TORONTO, April 04, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fi...

Venus Concept Submits FDA 510(k) Related to the Use of its Aime™ Next Generation Robotic Technology for Tissue Excision and Skin Resurfacing
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced it has submitted a 510(k...

Venus Concept (VERO) Reports Q4 Loss, Tops Revenue Estimates
Venus Concept (VERO) delivered earnings and revenue surprises of 33.33% and 0.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept Announces Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Revenue Guidance
TORONTO, March 28, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the thre...

Venus Concept Inc. to Present at the Maxim Virtual Growth Conference on March 28th
TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will pre...

Venus Concept Inc. to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16th
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will part...

Venus Concept to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 28, 2022
TORONTO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and f...

Venus Concept Receives FDA 510(k) Clearance of Venus BlissMAX for Non-Invasive Lipolysis of the Abdomen and Flanks, Cellulite Reduction and Muscle Conditioning
TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has received 510(...

Venus Concept Reports Preliminary Revenue Results for Fourth Quarter 2021
TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary unaudited reve...